106 results
8-K
EX-99.1
RNAC
Cartesian Therapeutics Inc
9 Apr 24
Regulation FD Disclosure
7:00am
-2024 Plan to treat ~30 patients PRIMARY ENDPOINT Proportion of MG Composite responders ( -point reduction) at Day 85 SECONDARY OBJECTIVES Safety … and no CNS involvement Designed to assess safety, tolerability, and manufacturing feasibility of Descartes-08 in patients with SLE Secondary
8-K
EX-99.1
hhuaun1axqvxtbt7
7 Mar 24
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
7:06am
8-K
EX-99.3
cvq6teaon5mifzahdi
8 Jan 24
Regulation FD Disclosure
8:45am
8-K
EX-99.1
kgfrgjx9x91u452cx71q
8 Jan 24
Regulation FD Disclosure
8:45am
DEFA14A
oq591z4q0nat74 sc8nz
13 Nov 23
Additional proxy soliciting materials
9:06am
8-K
EX-10.1
k8j nxq3s78
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-99.1
z16y643
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-2.1
l54 oko7afvrus
13 Nov 23
Entry into a Material Definitive Agreement
9:02am
8-K
EX-99.1
fl9yoc1kpv3
18 Nov 22
November 2022 Selecta Biosciences Corporate Presentation SELB
4:30pm